Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder

Nephrology

Volumn 16, Issue 6, 2011, Pages 588-594

  Jiang, Jian Qing ^a   Lin, Shan ^a   Xu, Peng Cheng ^a   Zheng, Zhen Feng ^a   Jia, Jun Ya ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

bone mineral density; chronic kidney disease mineral and bone disorder; osteoprotegerin

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CALCITONIN; CALCIUM; CREATININE; NITROGEN; OSTEOCALCIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHORUS; UREA;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE DEMINERALIZATION; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE MINERAL; CALCITONIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CHEMICAL ANALYSIS; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY DISEASE MINERAL AND BONE DISORDER; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; CREATININE BLOOD LEVEL; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMUR NECK; GLOMERULUS FILTRATION RATE; GREATER TROCHANTER; HEMODIALYSIS; HUMAN; HUMAN TISSUE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; NOMENCLATURE; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

ABSORPTIOMETRY, PHOTON; ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BONE DENSITY; CHINA; CHRONIC DISEASE; EARLY DIAGNOSIS; FEMALE; FEMUR; FEMUR NECK; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPROTEGERIN; PREDICTIVE VALUE OF TESTS; RENAL OSTEODYSTROPHY; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 80051696449     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01481.x     Document Type: Article

References (39)

1. Sherrard DJ, Hercz G, Pei Y, et al,. The spectrum of bone disease in chronic renal failure: An evolving disorder. Kidney Int. 1993; 43: 436-42. (Pubitemid 23162839)
2. Malluche HH, Monier-Faugere MC,. Renal bone disease. An unmet challenge for the nephrologist. Kidney Int. 1990; 38: 193-211. (Pubitemid 20324978)
3. Hruska KA, Teitelbaum SL,. Renal osteodystrophy. N. Engl. J. Med. 1995; 333: 166-74.
4. Caligara F, Giangrande A, Allaria P, Castiglioni A,. The PTH-calcium relationship curve in secondary hyperparathyroidism, an index of sensitivity and suppressibility of parathyroid glands. Nephrol. Dial. Transplant. 1996; 11 (Suppl 3): 136-41. (Pubitemid 26278604)
5. Malluche HH, Ritz E, Lange HP, et al,. Bone histology in incipient and advanced renal failure. Kidney Int. 1976; 9: 355-62.
6. Moe S, Drüeke T, Cunningham J, et al,. Kidney disease: Improving global outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int. 2006; 69: 1945-53. (Pubitemid 43924257)
7. Moe SM, Drüeke T,. Improving global outcomes in mineral and bone disorders. Clin. J. Am. Soc. Nephrol. 2008; 3 (Suppl 3): S127-30.
8. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al,. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006; 70: 771-80. (Pubitemid 44215354)
9. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC,. Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. 2004; l15: 1943-51. (Pubitemid 38822076)
10. Coen G, Ballanti P, Balducci A, et al,. Serum osteoprotegerin and renal osteodystrophy. Nephrol. Dial. Transplant. 2002; 17: 233-8. (Pubitemid 34157136)
11. Bucay N, Sarosi I, Dustan CR, et al,. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12: 1260-8. (Pubitemid 28213402)
12. Whyte MP, Obrecht SE, Finnegan PM, et al,. Osteoprotegerin deficiency and juvenile Paget's disease. N. Engl. J. Med. 2002; 347: 175-84. (Pubitemid 34764821)
13. Cundy T, Hegde M, Naot D, et al,. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum. Mol. Genet. 2002; 11: 2119-27. (Pubitemid 34994000)
14. Browner WS, Lui LY, Cummings SR,. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 2001; 86: 631-7. (Pubitemid 32207471)
15. Mesquita M, Demulder A, Damry N, et al,. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin. Chem. Lab. Med. 2009; 47: 339-46.
16. Morena M, Dupuy AM, Jaussent I, et al,. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol. Dial. Transplant. 2009; 24: 3389-97.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999; 130: 461-70. (Pubitemid 29135798)
18. Hofbauer LC, Schoppet M,. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-5. (Pubitemid 38988958)
19. Collin-Osdoby P,. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ. Res. 2004; 95: 1046-57. (Pubitemid 39557891)
20. Kato S, Chmielewski M, Honda H, et al,. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 2008; 3: 1526-33.
21. Riminucci M, Collins MT, Fedarko NS, et al,. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 2003; 112: 683-92. (Pubitemid 38057709)
22. Fliser D, Kollerits B, Neyer U, et al,. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J. Am. Soc. Nephrol. 2007; 18: 2600-8.
23. Kanbay M, Nicoleta M, Selcoki Y, et al,. Fibroblast growth factor 23 and fetuin A are independent predictors for the coronary artery disease extent in mild chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2010; 5: 1780-6.
24. Kagami S, Ohkido I, Yokoyama K, Shigematsu T, Hosoya T,. Rotegerin affects the responsiveness of fibroblast growth factor-23 to high oral phosphate intake. Clin. Nephrol. 2008; 70: 306-11.
25. Gerakis A, Hadjidakis D, Kokkinakis E, Apostolou T, Raptis S, Billis A,. Correlation of bone mineral density with the histological findings of renal osteodystrophy in patients on hemodialysis. J. Nephrol. 2000; 13: 437-43. (Pubitemid 32015745)
26. Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G,. A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am. J. Kidney Dis. 2001; 37: 1247-52. (Pubitemid 32525162)
27. Uemura H, Yasui T, Miyatani Y, et al,. Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women. J. Endocrinol. Invest. 2008; 31: 163-8. (Pubitemid 351596978)
28. Oh KW, Rhee EJ, Lee WY, et al,. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin. Endocrinol. (Oxf). 2005; 62: 92-8. (Pubitemid 40175289)
29. Fahrleitner A, Prenner G, Leb G, et al,. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 2003; 32: 96-106. (Pubitemid 36173817)
30. Moschen AR, Kaser A, Stadlmann S, et al,. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J. Hepatol. 2005; 43: 973-83. (Pubitemid 41627982)
31. Haas M, Leko-Mohr Z, Roschger P, et al,. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am. J. Kidney Dis. 2002; 39: 580-6. (Pubitemid 34194634)
32. Kazama JJ, Shigematsu T, Yano K, et al,. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am. J. Kidney Dis. 2002; 39: 525-32. (Pubitemid 34194628)
33. Wada T, Nakashima T, Hiroshi N, Penninger JM,. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol. Med. 2006; 12: 17-25. (Pubitemid 43089652)
34. Doumouchtsis KK, Kostakis AI, Doumouchtsis SK, et al,. Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients. J. Bone Miner. Metab. 2008; 26: 66-72. (Pubitemid 350307998)
35. Fahrleitner-Pammer A, Dobnig H, Dimai HP, et al,. The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. Clin. Nephrol. 2009; 71: 652-9.
36. Doumouchtsis K, Perrea D, Doumouchtsis S, et al,. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease. Ther. Apher. Dial. 2009; 13: 49-55.
37. Cianciolo G, La Manna G, Donati G, et al,. Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. Nephrol. Dial. Transplant. 2011; 26: 646-52.
38. Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y,. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 2007; 41: 165-74. (Pubitemid 47001824)
39. Vik A, Brodin E, Sveinbjørnsson B, Hansen JB,. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb. Haemost. 2007; 98: 148-54. (Pubitemid 47074191)